Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?

Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding.

¿Debemos utilizar con mayor frecuencia el cierre de orejuela de la aurícula izquierda? ¿Qué datos tenemos de la vida real?

One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed.

Researchers conducted an analysis of the National Cardiovascular Data Registry of the American College of Cardiology, which includes 366,814 patients implanted with the Watchman device.

The primary endpoint (PEP) was ischemic stroke, while the secondary endpoint (SEP) included death, hemorrhagic stroke, undetermined stroke, intracranial bleeding, any stroke, systemic embolism, and major bleeding.

Mean age was 76 years old, 58% of the patients were male, patient BMI was 30 [sic], over 90% of patients were hypertensive, 38% had diabetes, 25% had a prior stroke, 14% had a prior TIA, and 18% had a history of thromboembolism.

The HAS-BLED score was 3 and the CHA2DS2-VASc score was 4.8; 70% of patients experienced major bleeding, 42% experienced digestive bleeding, and 12% experienced intracranial bleeding.

Read also: WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World. Antiplatelet Therapy. Anticoagulation Scheme.

Atrial fibrillation was paroxysmal in 52% of cases; in all others, it was permanent or persistent.

Procedural success was 97%.

At discharge, 50% of patients received aspirin plus anticoagulation (warfarin or DOAC) and, to a lesser extent, anticoagulation or dual antiplatelet therapy.

Read also: Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI.

A one-year follow-up was conducted for 93.6% of patients.

The PEP was 1.53% (95% confidence interval: 1.39%-1.69%), the ischemic stroke rate was 2.19%, and all-cause mortality was 8.5%. The composite of stroke, systemic embolism, or death at a year was 10.7%. Major bleeding was 6.9% (mostly occurring within 45 days after discharge).

Conclusion

This study highlights the importance of the evolution of a cohort in the US with percutaneous closure of the left atrial appendage. Knowing the data, physicians and patients can make joint decisions on this therapy.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org .

Original Title: Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States.

Reference: Matthew J. Price, et al. J Am Coll Cardiol Intv 2022;15:741–750.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation, evidence level B, according to the current...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...